Related Experiment Video
Updated: Feb 27, 2026
12:22
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
34.2K
Targeted therapies for renal cell carcinoma
Edwin M Posadas1, Suwicha Limvorasak1, Robert A Figlin1
1Urologic Oncology Program &Translational Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA.
Nature Reviews. Nephrology
|July 11, 2017
Summary
Treatment for metastatic renal cell carcinoma (RCC) has advanced with new kinase and immune checkpoint inhibitors. Personalized medicine, using molecular approaches and biomarkers, is crucial for selecting optimal therapies and managing treatment value.
Area of Science:
- Oncology
- Translational Medicine
- Pharmacology
Background:
- Management of metastatic renal cell carcinoma (RCC) has evolved significantly.
- Historically, cytokine therapies offered limited efficacy and high toxicity for RCC.
- Current treatments include kinase inhibitors and immune checkpoint inhibitors.
Purpose of the Study:
- To review the molecular mechanisms underlying RCC and the development of targeted therapies.
- To discuss biomarkers for predicting treatment response in RCC.
- To evaluate the value of new agents considering clinical benefit, toxicity, and cost.
Main Methods:
- Review of current literature on RCC pathogenesis and therapeutic advancements.
- Analysis of molecular and sequencing approaches for personalized treatment selection.
- Framework for assessing the value of novel RCC therapies.
Main Results:
- Improved molecular understanding has driven the development of novel RCC therapies.
- Kinase and immune checkpoint inhibitors represent significant therapeutic progress.
- Personalization of therapy is increasingly important for optimizing patient outcomes.
Conclusions:
- Contemporary RCC treatment focuses on combinatorial and perioperative strategies.
- Biomarker discovery is essential for tailoring treatments to individual patients.
- Evaluating the value of new therapies is critical for sustainable cancer care.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
01:24Modified-Release Drug Delivery Systems: Site-Targeted
51
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51
02:49Cancer Therapies
10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K